The Central Finding This study reveals that lactate dehydrogenase A (LDHA), a key glycolytic enzyme, is upregulated in CD8+ T cells within the NSCLC tumor microenvironment, where it drives metabolic reprogramming that suppresses T cell anti-tumor function and promotes immune evasion.
Study Scale The authors generated a comprehensive single-cell atlas of 351,571 CD8+ T cells from 89 NSCLC patients, making this one of the largest single-cell immunology studies in lung cancer. This unprecedented scale allowed identification of 10 distinct CD8+ T cell states and the metabolic factors governing their functional trajectories.
Metabolic Immune Evasion NSCLC tumors create a hostile metabolic environment characterized by high glucose consumption and lactate accumulation. While much attention has focused on how tumor cell metabolism starves T cells of nutrients, this study shows that CD8+ T cells themselves undergo LDHA-driven metabolic changes that impair their cytotoxic function.
Clinical Relevance High LDHA expression in intratumoral CD8+ T cells correlated with poor responses to PD-1/PD-L1 immunotherapy in NSCLC patients, identifying LDHA inhibition as a potential strategy to enhance immunotherapy efficacy by restoring T cell metabolic fitness.
Single-Cell RNA-Sequencing The 89-patient cohort underwent single-cell RNA-sequencing (scRNA-seq) to profile gene expression at the individual cell level. After quality filtering, 351,571 CD8+ T cells were analyzed, spanning peripheral blood, tumor-adjacent normal tissue, and tumor tissue from treatment-naive and previously treated patients.
Ten CD8+ T Cell States Unsupervised clustering identified 10 distinct CD8+ T cell states including naive/stem-like, memory, effector, tissue-resident memory, exhausted progenitor, terminally exhausted, cytotoxic effector memory, proliferating, NK-like, and regulatory-like states. Each state had a characteristic gene expression profile reflecting distinct functional properties.
LDHA Expression Pattern LDHA expression was highest in terminally exhausted and effector CD8+ T cells and was enriched in intratumoral compared to peripheral blood T cells. This spatial enrichment within the TME suggests that tumor-derived signals - possibly through hypoxia, lactate, or checkpoint signaling - upregulate LDHA in CD8+ T cells after tumor infiltration.
Pseudotime Analysis Trajectory analysis using pseudotime algorithms mapped the developmental path of CD8+ T cells from naive precursors toward exhausted states. LDHA upregulation occurred progressively along the exhaustion trajectory, suggesting that glycolytic reprogramming is not the cause but a co-occurring feature of T cell dysfunction.
Glycolysis and Lactate Production LDHA catalyzes the final step of glycolysis, converting pyruvate to lactate while regenerating NAD+ needed for continued glucose metabolism. In CD8+ T cells with high LDHA activity, increased lactate production leads to intracellular acidification and altered NAD+/NADH ratios that impair mitochondrial function.
Mitochondrial Dysfunction High LDHA activity diverts pyruvate away from mitochondrial oxidative phosphorylation, reducing ATP production efficiency and generating reactive oxygen species (ROS). Mitochondrial dysfunction in exhausted T cells is a well-established cause of reduced cytokine production, impaired proliferative capacity, and diminished cytotoxic killing.
Epigenetic Consequences Metabolic state influences gene expression through epigenetic modifications. LDHA-high T cells showed altered chromatin accessibility at loci controlling effector cytokine genes (IFN-gamma, TNF-alpha, IL-2), suggesting that metabolic reprogramming causes stable epigenetic changes that reinforce the exhausted phenotype.
Lactate Signaling Beyond its metabolic role, lactate itself functions as a signaling molecule that suppresses T cell activity. LDHA-driven lactate export into the TME activates lactate receptor GPR81 on immune cells and contributes to the acidic microenvironment that further impairs T cell function through pH-sensitive transcriptional programs.
Immunotherapy Cohort Analysis CD8+ T cell LDHA expression was analyzed in a subgroup of patients who received PD-1/PD-L1 checkpoint inhibitors. High LDHA expression in intratumoral CD8+ T cells significantly correlated with poor objective response rates and shorter progression-free survival.
LDHA-High vs. LDHA-Low Outcomes Patients whose tumors contained CD8+ T cells with low LDHA expression showed 3-fold higher response rates to immunotherapy compared to LDHA-high patients. Kaplan-Meier analysis demonstrated clearly separated survival curves, with LDHA-low patients achieving longer durable responses.
Independence from PD-L1 Multivariate analysis showed that CD8+ LDHA expression was an independent predictor of immunotherapy response even after adjusting for PD-L1 expression and tumor mutational burden - the two currently used clinical predictors. This suggests LDHA captures an independent biological dimension of immunotherapy resistance.
Functional Validation Ex vivo experiments with CD8+ T cells from patient tumors confirmed that LDHA inhibition (using the LDHA inhibitor FX11) partially restored cytokine production and cytotoxic killing capacity in exhausted T cells, providing mechanistic support for LDHA as a therapeutic target.
Metabolic Competition NSCLC tumor cells preferentially utilize aerobic glycolysis (Warburg effect), consuming large amounts of glucose and generating lactate even in the presence of oxygen. This metabolic competition depletes the glucose available for infiltrating T cells and creates a lactate-rich, acidic microenvironment hostile to T cell function.
HIF-1alpha Signaling Tumor hypoxia activates HIF-1alpha in both cancer cells and T cells. In CD8+ T cells, HIF-1alpha promotes LDHA expression and glycolytic programming, while simultaneously upregulating PD-1 and other checkpoint molecules. This creates a coordinated transcriptional program linking hypoxia to both metabolic and checkpoint-mediated T cell suppression.
CAF and TAM Contributions Cancer-associated fibroblasts and tumor-associated macrophages further exacerbate the metabolic hostile environment. CAFs compete for glucose and glutamine, while M2 TAMs produce immunosuppressive cytokines (IL-10, TGF-beta) that promote glycolytic programming and LDHA upregulation in T cells.
Spatial Metabolic Gradients Within NSCLC tumors, metabolic conditions vary spatially. Hypoxic tumor cores with high lactate accumulation show the highest CD8+ T cell LDHA expression and exhaustion markers, while tumor periphery regions with better oxygen and nutrient access contain more metabolically fit T cells capable of anti-tumor activity.
LDHA Inhibition as Immunotherapy Adjunct Small molecule LDHA inhibitors (FX11, NHI compounds, galloflavin) have shown pre-clinical anti-tumor and T cell rescue activity. Combining LDHA inhibition with PD-1/PD-L1 blockade could simultaneously boost T cell metabolic fitness and release checkpoint brakes, potentially achieving synergistic anti-tumor immunity.
Metabolic Reprogramming Strategies Beyond LDHA, broader strategies to improve T cell metabolic fitness in the TME include supplementing with alternative fuels (fatty acids, glutamine), targeting HIF-1alpha to reduce glycolytic programming, enhancing mitochondrial biogenesis with PGC-1alpha agonists, and buffering lactate-induced acidification.
LDHA as Patient Stratification Biomarker CD8+ T cell LDHA expression measured from tumor biopsies or potentially from liquid biopsy T cell isolation could stratify patients for immunotherapy. Patients with LDHA-low intratumoral T cells may be predicted to respond well to standard ICI, while LDHA-high patients may require combination metabolic-immunotherapy approaches.
Limitations and Future Studies This study's mechanistic findings are primarily correlative from single-cell data. Causal evidence requires genetic manipulation (T cell-specific LDHA knockout) in immunocompetent mouse models. Clinical trials combining LDHA inhibitors with ICIs in NSCLC are needed to determine whether the metabolic rescue hypothesis translates to improved patient outcomes.